Mauna Kea Technologies Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sacha Loiseau

Chief Executive Officer (CEO)

€172.6k

Compensación total

Porcentaje del salario del CEO	48.6%
Permanencia del CEO	24.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sacha Loiseau en comparación con los beneficios de Mauna Kea Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-€4m
Sep 30 2023	n/a	n/a	-€3m
Jun 30 2023	n/a	n/a	-€2m
Mar 31 2023	n/a	n/a	-€7m
Dec 31 2022	€173k	€84k	-€11m
Sep 30 2022	n/a	n/a	-€12m
Jun 30 2022	n/a	n/a	-€13m
Mar 31 2022	n/a	n/a	-€13m
Dec 31 2021	€207k	n/a	-€13m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€13m
Mar 31 2021	n/a	n/a	-€13m
Dec 31 2020	€325k	€156k	-€13m
Sep 30 2020	n/a	n/a	-€13m
Jun 30 2020	n/a	n/a	-€14m
Mar 31 2020	n/a	n/a	-€15m
Dec 31 2019	€252k	€164k	-€15m
Sep 30 2019	n/a	n/a	-€15m
Jun 30 2019	n/a	n/a	-€14m
Mar 31 2019	n/a	n/a	-€13m
Dec 31 2018	€639k	€197k	-€13m
Sep 30 2018	n/a	n/a	-€12m
Jun 30 2018	n/a	n/a	-€11m
Mar 31 2018	n/a	n/a	-€11m
Dec 31 2017	€256k	€205k	-€10m

Compensación vs. Mercado: La compensación total de Sacha($USD185.13K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD345.26K).

Compensación vs. Ingresos: La compensación de Sacha ha sido consistente con los resultados de la empresa en el último año.

CEO

Sacha Loiseau

24.3yrs

Permanencia

€172,636

Compensación

Mr. Alexandre Loiseau, also known as Sacha, Ph.D. has been Chief Executive Officer of Mauna Kea Technologies SA since October 04, 2022. He serves as Venture Partner at Elaia Partners SAS since joining from...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexandre Loiseau	Co-Founder	24.3yrs	€172.64k	sin datos
Come de La Tour du Pin	Chief Financial Officer	less than a year	sin datos	sin datos
Nathalie Lecoq	Chief Operating Officer	1.3yrs	sin datos	sin datos
Frederic Banegas	Chief Technology Officer	3.3yrs	sin datos	sin datos
François Lacombe	Chief Scientific Officer	no data	sin datos	sin datos
Daryl Donatelli	Vice President of Global Marketing & U.S. Sales	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0P5I se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexandre Loiseau	Co-Founder	13yrs	€172.64k	sin datos
Molly O'Neill	Independent Director	6.3yrs	€19.00k	sin datos
Christopher McFadden	Independent Director	16.3yrs	€20.00k	sin datos
Claire Biot	Independent Director	3.8yrs	€15.00k	sin datos
Jacquelien Ten Dam	Independent Director	3.4yrs	€20.00k	sin datos

6.3yrs

Permanencia media

Junta con experiencia: La junta directiva de 0P5I se considera experimentada (6.3 años de antigüedad promedio).

Mauna Kea Technologies Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Recent updates

No longer forecast to breakeven

Insufficient new directors

Full year 2023 earnings released: €0.076 loss per share (vs €0.25 loss in FY 2022)

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

Insufficient new directors

New minor risk - Financial data availability

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

No longer forecast to breakeven

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

New major risk - Revenue and earnings growth

No longer forecast to breakeven

No longer forecast to breakeven

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

No longer forecast to breakeven

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media